• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Magnetic resonance imaging-guided fibrosis ablation plus pulmonary vein isolation non-superior to pulmonary vein isolation alone in preventing atrial arrhythmia recurrence: The DECAAF II trial

byJake EngelandMichael Pratte
June 22, 2022
in Cardiology, Chronic Disease, Emergency
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The DECAAF II randomized controlled trial demonstrated that among patients with persistent atrial fibrillation, magnetic resonance imaging (MRI)-guided fibrosis-targeted ablation in addition to pulmonary vein isolation (PVI) did not reduce the recurrence of atrial arrhythmias compared to PVI alone.

2. Adverse outcomes were significantly increased among the MRI-guided ablation plus PVI group compared to the PVI only cohort.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Recurrence of atrial arrhythmias, such as atrial fibrillation (AF), is common after ablation procedures. Given that left-atrial fibrosis seen on delayed-enhancement magnetic resonance imaging (MRI) was shown to be associated with atrial arrhythmia recurrence, it was hypothesized that targeting fibrosis using MRI may decrease recurrence following procedures. The DECAAF II trial investigated whether utilizing delayed-enhancement MRI to target atrial fibrosis in addition to performing the conventional treatment of pulmonary vein isolation (PVI) was superior in decreasing atrial arrhythmia recurrence compared to PVI alone in patients with persistent AF. This study was conducted in 44 centres across the United States, Europe, and Australia between July 2016 and January 2020. Patients were included if they had persistent AF (7 days or longer) and were undergoing their first atrial ablation procedure. Patients were randomized to either receive MRI-guided fibrosis ablation and PVI (n= 421) or PVI alone (n= 422). The primary outcome was the first confirmed recurrence of atrial arrhythmia. Atrial arrhythmia recurrence was not significantly reduced in the MRI plus PVI group compared to the PVI alone cohort (hazard ratio [HR]: 0.95 [95% CI: 0.77-1.17]; p= 0.63). There was no significant difference in the incidence of all three types of arrhythmias (AF, atrial flutter, and atrial tachycardia). Quality of life was also assessed using the Toronto Atrial Fibrillation Symptom Severity Scale; there was no significant difference in scores between cohorts (mean difference from baseline to 12 months: -0.38 points [95% CI: -1.23 to 0.47]). MRI-guided ablation plus PVI demonstrated a significantly increased risk of serious adverse events compared to PVI alone (2.2% vs 0%; p= 0.001); in particular, stroke appeared to be the most common significant adverse event. Overall, this randomized controlled trial demonstrated that MRI-guided fibrosis-targeted ablation plus PVI did not reduce the incidence of atrial arrhythmia recurrence compared to PVI alone; additionally, this procedure increased the risk of adverse events. One limitation of this study, however, is that the follow-up period was relatively short (up to 18 months), and perhaps a longer follow-up could reveal a significant difference between cohorts.

Click to read the study in JAMA

Relevant Reading: Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation

Image: PD

RELATED REPORTS

Wellness Check: Sleep

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ablationatrial fibrillation
Previous Post

SALT-ED: Normal Saline versus Balanced Crystalloids in Noncriticaly Ill Adults [Classics Series]

Next Post

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

RelatedReports

Decline in adolescent sleep duration over past 20 years
Wellness

Wellness Check: Sleep

July 7, 2022
#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk
StudyGraphics

#VisualAbstract: New-onset atrial fibrillation following hospitalization for pneumonia associated with increased thromboembolic risk

June 28, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Cardiology Classics

The EAST-AFNET 4 trial: Early rhythm control therapy for atrial fibrillation [Classics Series]

June 13, 2022
Stroke expansion following intra-arterial therapy may explain worse outcomes
Cardiology

Reduced bleeding risk with asundexian compared to apixaban in patients with atrial fibrillation

April 19, 2022
Next Post
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant

AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19

Atrial fibrillation-specific management increases days alive and out of hospital

Risk of myocarditis or pericarditis after COVID-19 mRNA vaccination is highest among younger males

Reduced doses of human papillomavirus vaccine may be effective in preventing condyloma

Human papillomavirus vaccine effective in preventing infections in the United States

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Hybrid immunity protects against infection with omicron variant of COVID-19
  • #VisualAbstract: Tirzepatide Once Weekly for the Treatment of Obesity
  • Wellness Check: Sleep
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.